Multicell Technologies awarded patent for cancer, hepatitis-fighting platform
By Elizabeth W. Lorenz
PBN Staff Writer
9/3/14
WOONSOCKET – MultiCell Technologies Inc. has been issued a U.S. patent for drug compositions and platform technologies, which are designed treat virus infections and cancer.
The patent seeks to address what the company calls an unmet medical need. The therapeutics will be used to treat hepatitis B and hepatitis C, as well as hepatocellular carcinoma, which is one of the leading causes of cancer deaths worldwide and the fourth most common form of liver cancer. According to the National Cancer Institute, there are more than 1 million cases of hepatocellular carcinoma worldwide and only 16 percent of patients diagnosed with primary liver cancer live longer than five years.
After studying mouse cancer models, MultiCell Technologies found that a combination of MCT-465, a noncoding doubled-stranded RNA therapeutic and MCT-475, a recombinant immunoglobulin-peptide therapeutic, were able to stimulate the animal’s immune system to eradicate an engrafted tumor. The drug combination also promoted a protective immunity toward any new tumor variants by producing more cytokine proteins (interferon gamma and interleukin-2). The proteins produced antigen-specific T cells, leaving immunized mice with significantly lower virus levels than those that weren’t.
Aside from finding new anti-tumor immune cells, findings also provided insight about the immune memory in animals.
MultiCell Technologies Inc. is a clinical-stage biopharmaceutical company based in Woonsocket that develops novel therapeutics and discovery tools in order to treat neurological disorders, hepatic disease and cancer.
Aussichten für Heute:
Overall Average: 96% Strong Buy
Support & Resistance More
2nd Resistance Point 0.0026
1st Resistance Point 0.0024
Last Price 0.0021
1st Support Level 0.0017
2nd Support Level 0.0012
digger2.0
Dachte hier würde auch aktuell etwas gepostet,
aber sieht ja nicht so aus!
Immerhin 40% gemacht Gestern!
Häufig gestellte Fragen zur MultiCell Technologies Aktie und zum MultiCell Technologies Kurs
Der aktuelle Kurs der MultiCell Technologies Aktie liegt bei 0,000001 €.
Für 1.000€ kann man sich 1.000.000.000 MultiCell Technologies Aktien kaufen.
Das Tickersymbol der MultiCell Technologies Aktie lautet MCET.
Das 52-Wochen-Hoch der MultiCell Technologies Aktie liegt bei 0,00 $.
Das 52-Wochen-Tief der MultiCell Technologies Aktie liegt bei 0,00 $.
Das Allzeithoch von MultiCell Technologies liegt bei 0,01 $.
Das Allzeittief von MultiCell Technologies liegt bei 0,00 $.
Die Volatilität der MultiCell Technologies Aktie liegt derzeit bei 1.554,27%. Diese Kennzahl zeigt, wie stark der Kurs von MultiCell Technologies in letzter Zeit schwankte.
MultiCell Technologies hat seinen Hauptsitz in USA.
MultiCell Technologies gehört zum Sektor Biotechnologie.
Nein, MultiCell Technologies zahlt keine Dividenden.